Emergent BioSolutions presents transformation update, Q2 results, $40M restructuring savings and revised FY26 guidance

Emergent BioSolutions presented a business update highlighting Q2 momentum in medical countermeasures, a restructuring delivering ~$40M annualized savings and revised FY2026 guidance.Key Highlights:Original SEC Filing: Emergent BioSolutions Inc. [ EBS ] - 8-K - Sep. 14, 2026This is an AI-powered su…